krn-7000 and Haemophilus-Infections

krn-7000 has been researched along with Haemophilus-Infections* in 1 studies

Other Studies

1 other study(ies) available for krn-7000 and Haemophilus-Infections

Article	Year
Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine, 2010, Jul-12, Volume: 28, Issue:31 The efficacy of alpha-galactosylceramide (alpha-GalCer) as a mucosal adjuvant was examined. Mice were immunized intranasally with nontypeable Haemophilus influenzae (NTHi) P6 protein and alpha-GalCer. P6-specific antibody responses in the form of P6-specific IgA in nasal washes and serum IgG titers were significantly elevated. Splenic CD4(+) T cells expressed P6-specific Th1 and Th2 cytokine mRNA. In addition, NTHi was quantified in nasal washes following NTHi challenges, and the clearance of NTHi from the nasopharynx was also enhanced. These results indicate that alpha-GalCer might be an effective mucosal adjuvant. Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibodies, Bacterial; Antibody Formation; Bacterial Outer Membrane Proteins; CD4-Positive T-Lymphocytes; Dendritic Cells; Galactosylceramides; Haemophilus Infections; Haemophilus influenzae; Haemophilus Vaccines; Immunity, Mucosal; Immunoglobulin A; Immunoglobulin G; Mice; Mice, Inbred BALB C; Nasopharynx; Natural Killer T-Cells	2010

Article

Year

Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx.

Vaccine, 2010, Jul-12, Volume: 28, Issue:31

The efficacy of alpha-galactosylceramide (alpha-GalCer) as a mucosal adjuvant was examined. Mice were immunized intranasally with nontypeable Haemophilus influenzae (NTHi) P6 protein and alpha-GalCer. P6-specific antibody responses in the form of P6-specific IgA in nasal washes and serum IgG titers were significantly elevated. Splenic CD4(+) T cells expressed P6-specific Th1 and Th2 cytokine mRNA. In addition, NTHi was quantified in nasal washes following NTHi challenges, and the clearance of NTHi from the nasopharynx was also enhanced. These results indicate that alpha-GalCer might be an effective mucosal adjuvant.

Topics: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibodies, Bacterial; Antibody Formation; Bacterial Outer Membrane Proteins; CD4-Positive T-Lymphocytes; Dendritic Cells; Galactosylceramides; Haemophilus Infections; Haemophilus influenzae; Haemophilus Vaccines; Immunity, Mucosal; Immunoglobulin A; Immunoglobulin G; Mice; Mice, Inbred BALB C; Nasopharynx; Natural Killer T-Cells

2010